Hammer Lab

Location and Contact Information

Hammer Lab
650 W 168th Street
William Black Building, BB-1017
New York, NY 10032
United States

Principal Investigators

The Hammer Lab provides research support infrastructure for a wide range of investigator-initiated and Clinical Research Network-sponsored HIV treatment and prevention studies.

Select Publications

  • Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC (for the ACTG 175 study team). A trial of nucleoside monotherapy vs. combination therapy in HIV-infected adults with CD4 cell counts between 200 and 500 per cubic millimeter: NIAID-sponsored AIDS clinical trials group study 175. N Engl J Med. 1996;335:1081-1096.

  • Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA (for the AIDS clinical trials group 320 study team). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.

  • Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 1: Cellular and humoral immune responses. Ann Intern Med. 2001;134:761-776.

  • Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: Genetic factors and implications for antiretroviral therapeutics. Ann Intern Med. 2001;134:978-996.

  • Hammer SM. Increasing choices for HIV therapy. N Engl J Med. 2002;346:2022-2023.

  • Hammer S, Gibb D, Havlir D, Mofenson L, VAn Beek I, Vella S, Vareldzis B, Perriens J and the WHO Writing Committee: Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. World Health Organization, April 2002, available at www.who.int.

  • Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, and Mellors JW (for the AIDS clinical trials group 398 study team). Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. J Am Med Assoc. 2002;288:169-180.

  • Hammer SM, Bassett R, Squires KE, Fischl M, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, and DeGruttola V. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther. 2003;8:507-518.

  • Hammer SM, Mofenson L, Havlir D, Vitorio M, Perriens J and the WHO Writing Committee: Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 version. World Health Organization, December 2003, available at www.who.int.

  • Hammer SM. Clinical practice. Management of newly diagnosed HIV infection. N Engl J Med. 2005;353:1702-1710.

  • Sobieszczyk ME, Jones J, Wilkin T, Hammer SM. Advances in antiretroviral therapy. Top HIV Med. 2006;14:36-62.

  • Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. JAMA 2006;296:827-43.

  • Gripshover BM, Ribaudo H, Santana J, Gerber JG, Campbell TB, Hogg E, Jarocki B, Hammer SM, Kuritzkes DR; A5118 Team. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006;11:619-23.

  • Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society--USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med. 2006;14:827-43.

  • Hammer S, Riley A, Calmy A, Harries A, Duncombe C, Havlir D, Katabira E, Scano F, Malkin JE, Lange J, Mukerjee J, Currier J, Mofenson L, Harrington M, Schechter M, Kumarasamy N, Sow PS, Munderi P, Ojoo S, Cahn P, Phanuphak P, Eholie S, El Sadr W, Rodriguez W: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2006 revision. World Health Organization, August 2006, available at www.who.int.

  • Taylor BS, Sobieszczyk ME, McCutchan FE and Hammer SM: The challenge of HIV-1 subtype diversity. NEJM 2008;358:1590-1602.

  • Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM and Richman DD: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society - USA Panel. Clin Infect Dis 2008;47:266-285

  • Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JSG, Richman DD, Yeni PG and Volberding PA: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society – USA Panel. JAMA 2008; 300:555-570.

  • Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S and Squires K: Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 2008;9:11-25